Cambridge Healthtech Institute’s 8th Annual

Liquid Biopsy for Disease Management

Illuminating and Accelerating the Path from Discovery to Clinical Use

August 21-22, 2023

The 8^th annual Liquid Biopsy for Disease Management: From Discovery to Clinical Use conference will review new liquid biopsies coming on the market that have increased sensitivity and are robust enough for clinical applications for measuring treatment response, diagnosing disease recurrence, detecting multicancer at early stages, assessing minimal residue disease, monitoring disease progression, and determining prognosis. A thorough investigation of biomarkers and their clinical translation will be evaluated, including CTCs, cfDNA, exosomes, and EVs.

Coverage will include, but is not limited to:

Using liquid biopsies to alter cancer treatment
Undergoing molecular subtyping of tumors
Detecting minimal residual disease with EVs, CTCs, ctDNA
Identifying actionable mutations in CTCs to guide selection of therapy
Advancing early detection
Understanding molecular dynamics of CTCs with a higher tendency to metastasize
Discovering and validating new biomarkers

The deadline for priority consideration is January 30, 2023.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: